Precision Biosciences (DTIL) Operating Leases (2020 - 2026)
Precision Biosciences (DTIL) posted quarterly Operating Leases of $6.0 million for Q1 2026, little changed year-over-year from $6.0 million in Q1 2025, and up 23.48% quarter-over-quarter from $4.9 million in Q4 2025.
Precision Biosciences (DTIL) Operating Leases (2020 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Operating Leases for 7 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases changed 0.02% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (changed 0.02% YoY), while the FY2025 annual figure was $4.9 million, down 23.53% from the prior year.
- Operating Leases rose to $6.0 million in Q1 2026 per DTIL's latest filing, from $4.9 million in the prior quarter.
- Across five years, Operating Leases topped out at $7.7 million in Q4 2023 and bottomed at $1.1 million in Q4 2022.
- Historically, Operating Leases has averaged $5.2 million across 5 years, with a median of $5.9 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Leases slumped 78.0% — and 2023, when it surged 629.27%.
- Precision Biosciences' Operating Leases stood at $1.1 million in 2022, then soared by 629.27% to $7.7 million in 2023, then dropped by 17.08% to $6.4 million in 2024, then retreated by 23.53% to $4.9 million in 2025, then grew by 23.48% to $6.0 million in 2026.
- Business Quant data shows DTIL's Operating Leases at $6.0 million in Q1 2026, $4.9 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | Precision Biosciences | 225.86 Mn | 138.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.68 Mn |
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 6.75 Mn |
| Jun 30, 2025 | 5.68 Mn |
| Mar 31, 2025 | 6.05 Mn |
| Dec 31, 2024 | 6.40 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 7.09 Mn |
| Mar 31, 2024 | 7.41 Mn |
| Dec 31, 2023 | 7.72 Mn |
| Jun 30, 2023 | 3.17 Mn |
| Mar 31, 2023 | 2.23 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 3.31 Mn |
| Jun 30, 2022 | 3.82 Mn |
| Mar 31, 2022 | 4.33 Mn |
| Dec 31, 2021 | 4.81 Mn |
| Sep 30, 2021 | 6.97 Mn |
| Jun 30, 2021 | 7.52 Mn |